Research & Clinical Trials

There are currently more than 100 ongoing research projects at Miller Children’s & Women’s. Our studies focus on cancer, heart disease, infectious diseases, lung/respiratory, perinatal care and more. To find a clinical study that may be of interest to you, please use the search box in the left column.

283-22 | Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Trial Number: 283-22

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myoblastic Leukemia (AML), Leukemia

Conducted at: Main Campus

Participant Age Range: up to 22 Years

Participant Gender: Any

Enrolling Participants: Yes

313-22 | A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Trial Number: 313-22

Condition: Bone Cancer

Conducted at: Main Campus

Participant Age Range: up to 50 Years

Participant Gender: Any

Enrolling Participants: Yes

925-19 | Immediate Postpartum Glucose Tolerance Testing Among Gestational Diabetics: A Comparison to the Gold Standard

Trial Number: 925-19

Conditions: Diabetes, Gestational Diabetes/ Diabetes During Pregnancy

Conducted at: Main Campus

Participant Age Range: 18 years and older

Participant Gender: Female

Enrolling Participants: Yes

470-24 | Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Trial Number: 470-24

Conducted at: Main Campus

Participant Age Range: up to 18 Years

Participant Gender: Any

Enrolling Participants: Yes

213-21 | Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Trial Number: 213-21

Conducted at: Main Campus

Participant Age Range: 6 years to 17 years

Participant Gender: Any

Enrolling Participants: Yes

417-23 | Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Trial Number: 417-23

Conducted at: Main Campus

Participant Age Range: 6 years to 17 years

Participant Gender: Any

Enrolling Participants: Yes

We use cookies to give you the best experience. By using our site, you agree to our use of cookies. Please review our privacy policy to learn more.